Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus） (ECO)

March 6, 2026 updated by: Shu Peng

Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer

This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and predict treatment response and prognosis.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Built upon retrospective cohorts for model development and rigorously validated in prospective cohorts, the proposed AI predictive model integrates multimodal data (radiomics, pathomics, genomics, and multi-omics)-each reflecting distinct dimensions of tumor heterogeneity-to enable joint prediction of treatment response and clinical outcomes.

Study Type

Observational

Enrollment (Estimated)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Other (Non U.s.)
      • Wuhan, Other (Non U.s.), China, 430030
        • Recruiting
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contact:
        • Contact:
        • Principal Investigator:
          • Shu Peng, Doctor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with esophgeal cancer and have received treatment in Tongji hospital

Description

Inclusion Criteria:

  1. Histopathologically diagnosed esophageal cancer
  2. Complete baseline clinical data available (including demographic characteristics, ECOG performance score, TNM staging, etc.)
  3. No other primary malignant tumors
  4. Provision of informed consent
  5. Availability of pre-treatment CT imaging

Exclusion Criteria:

  1. Imaging data quality insufficient for analysis
  2. Presence of another primary malignant tumor
  3. Severe systemic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
neoadjuvant therapy cohort
received neoadjuvant therapy and esophagectomy
conservative treatment
concervative treatment includes chemo/immuno/radiotherapy and targeted theray
Endoscopic submucosal dissection (ESD)
Surgical resection cohort
neither neoajuvant therapy nor anti-tumor treatment prior to surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
overall survival
Time Frame: From enrollment to the end of treatment at 3 years
overall survival rate in 3-years
From enrollment to the end of treatment at 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shu Peng

Collaborators

Zhongnan Hospital
Henan Provincial People's Hospital
The First Affiliated Hospital of Henan University of Science and Technology
Renmin Hospital of Wuhan University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2025

Primary Completion (Estimated)

September 30, 2030

Study Completion (Estimated)

September 30, 2030

Study Registration Dates

First Submitted

January 12, 2026

First Submitted That Met QC Criteria

January 12, 2026

First Posted (Actual)

January 21, 2026

Study Record Updates

Last Update Posted (Actual)

March 10, 2026

Last Update Submitted That Met QC Criteria

March 6, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 4059393

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

In accordance with the institution's data confidentiality requirements

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe